

DAFTAR PUSTAKA

Adhikary, A. *et al.* (2010) 'Theaflavins retard human breast cancer cell migration by inhibiting NF- κ B via p53-ROS cross-talk', *FEBS Letters*. Federation of European Biochemical Societies, 584(1), pp. 7–14. doi: 10.1016/j.febslet.2009.10.081.

Alharbi, K. S. *et al.* (2022) 'Role of Medicinal plant-derived Nutraceuticals as a potential target for the treatment of breast cancer', *Journal of Food Biochemistry*, 46(12), pp. 1–18. doi: 10.1111/jfbc.14387.

American Cancer Society. Breast Cancer Facts & Figures 2019-2020. Atlanta: American Cancer Society, Inc. 2019.

American Society of Clinical Oncology (2023) 'Breast Cancer : Statistics'.

Amitha, H. and Selvamani, I. (2018) 'A Survey on Automatic Breast Cancer Grading of Histopathological Images', *2018 International Conference on Control, Power, Communication and Computing Technologies, ICCPCCT 2018*. IEEE, pp. 185–189. doi: 10.1109/ICCPCCT.2018.8574291.

Arnold, M. *et al.* (2022) 'Current and future burden of breast cancer: Global statistics for 2020 and 2040', *Breast*. Elsevier Ltd, 66(August), pp. 15–23. doi: 10.1016/j.breast.2022.08.010.

Ashariati, A. (2019) 'Manajemen Kanker Payudara Komprehensif', *Journal of Chemical Information and Modeling*, 53(9), pp. 1689–1699. Available at: [http://repository.unair.ac.id/96210/2/Manajemen Kanker Payudara Komprehensif.pdf](http://repository.unair.ac.id/96210/2/Manajemen_Kanker_Payudara_Komprehensif.pdf).

Burcu Firatligil-Yildirim, et al. "Recent Advances in Lab-On-a-Chip Systems for Breast Cancer Metastasis Research." Royal Society of Chemistry, 1 Jan. 2023, <https://doi.org/10.1039/d2na00823h>.

Cathcart-Rake, E. J., Ruddy, K. J., Bleyer, A., & Johnson, R. H. (2021). Breast Cancer in Adolescent and Young Adult Women Under the Age of 40 Years. *JCO Oncology Practice*, 17(6), 305–313. <https://doi.org/10.1200/op.20.00793>

Chan, P. F. and Hamid, R. A. (2021) 'An overview of breast cancer: Classification and related signaling pathways', *Progress in Microbes and Molecular Biology*, 4(1). doi: 10.36877/pmmb.a0000194.

Chang, Y., Zuka, M., Perez-Pinera, P., Astudillo, A., Mortimer, J., Berenson, J., & Deuel, T. (2007). Secretion of PLEIOTROPHIN stimulates breast cancer progression through remodeling of the tumor microenvironment. *Proceedings of the National Academy of Sciences*, 104(26), 10888–10893. <https://doi.org/10.1073/pnas.0704366104>

Clemons, M. and Goss, P. (2001) 'estrogen and the risk of breast cancer', *English*

Journal, 344(4), pp. 276–285. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11027744>.

Downs, B. and Wang, S. M. (2016) 'Epigenetic changes in BRCA1-mutated familial breast cancer', *Physiology & behavior*, 176(1), pp. 139–148. doi: 10.1016/j.cancergen.2015.02.001.Epigenetic.

Feng, Yixiao, et al. "Breast Cancer Development and Progression: Risk Factors, Cancer Stem Cells, Signaling Pathways, Genomics, and Molecular Pathogenesis." *Genes & Diseases*, vol. 5, no. 2, June 2018, pp. 77–106, www.ncbi.nlm.nih.gov/pmc/articles/PMC6147049/, <https://doi.org/10.1016/j.gendis.2018.05.001>.

Ganguly, D., Schmidt, M. O., Coleman, M., Ngo, T.-V. C., Sorrelle, N., Dominguez, A. T. A., Murimwa, G. Z., Toombs, J. E., Lewis, C., Fang, Y. V., Valdes-Mora, F., Gallego-Ortega, D., Wellstein, A., & Brekken, R. A. (2023). Pleiotrophin drives a prometastatic immune niche in breast cancer. *Journal of Experimental Medicine*, 220(5). <https://doi.org/10.1084/jem.20220610>

Ikhlas, M., Ferianto, D., Syamsu, S. A., Ganda, I. J., Smaradania, N., Sampepajung, E., Anggita, C. A., & Faruk, M. (2024). Pleiotrophin serum level and metastasis occurrence in breast cancer patients. *Breast Disease*, 43(1), 93–98. <https://doi.org/10.3233/bd-249003>

Laconi, E., Marongiu, F., & DeGregori, J. (2020). Cancer as a disease of old age: Changing Mutational and Microenvironmental Landscapes. *British Journal of Cancer*, 122(7), 943–952. <https://doi.org/10.1038/s41416-019-0721-1>

Li, Y., Zheng, J., Deng, Y., Deng, X., Lou, W., Wei, B., Xiang, D., Hu, J., Zheng, Y., Xu, P., Yao, J., Zhai, Z., Zhou, L., Yang, S., Wu, Y., Kang, H., & Dai, Z. (2022). Global burden of female breast cancer: Age-period-cohort analysis of incidence trends from 1990 to 2019 and forecasts for 2035. *Frontiers in Oncology*, 12. <https://doi.org/10.3389/fonc.2022.891824>

Liu, S. et al. (2021) 'Discovery of PTN as a serum-based biomarker of pro-metastatic prostate cancer', *British Journal of Cancer*. Springer US, 124(5), pp. 896–900. doi: 10.1038/s41416-020-01200-0.

Ma, J. et al. (2017) 'Pleiotrophin as a potential biomarker in breast cancer patients', *Clinica Chimica Acta*. Elsevier B.V, 466, pp. 6–12. doi: 10.1016/j.cca.2016.12.030.

Papadimitriou, E. et al. (2009) 'Roles of pleiotrophin in tumor growth and angiogenesis', *European Cytokine Network*, 20(4), pp. 180–190. doi: 10.1684/ecn.2009.0172.

Morrow M, Burstein H J, Harris J R. 2015. Malignant Tumors of the Breast. In: *Cancer Principle and practice of oncology*. 10th ed. Devita V T, Lawrence T S, Rosenberg S A. Philadelphia. Walter Kluwer. 1117-1156.

Papadimitriou, E. et al. (2016) 'Pleiotrophin and its receptor protein tyrosine

phosphatase beta/zeta as regulators of angiogenesis and cancer', *Biochimica et Biophysica Acta - Reviews on Cancer*. Elsevier B.V., 1866(2), pp. 252–265. doi: 10.1016/j.bbcan.2016.09.007.

Pourriahi, R., Omranipour, R., Alipour, S., Hajimaghsoudi, L., Mashoori, N., Kenary, A. Y., Motamedi, M., Tavakol, M., Mohammadzadeh, M., Hessamiazar, S., Shabani, S., Mahmoodi, F., Goodarzi, M. M., & Eslami, B. (2023). Clinical characteristics of breast cancer patients admitted to academic surgical wards in Tehran, Iran: An analytical cross-sectional study. *BMC Women's Health*, 23(1). <https://doi.org/10.1186/s12905-023-02637-0>

Perez-Pinera, P., Chang, Y. and Deuel, T. F. (2007) 'Pleiotrophin, a multifunctional tumor promoter through induction of tumor angiogenesis, remodeling of the tumor microenvironment and activation of stromal fibroblasts', *Cell Cycle*, 6(23), pp. 2877–2883. doi: 10.4161/cc.6.23.5090.

Pisanò, M. *et al.* (2011) 'A new mutation of BRCA2 gene in an Italian healthy woman with familial breast cancer history', *Familial Cancer*, 10(1), pp. 65–71. doi: 10.1007/s10689-010-9389-7.

Polyak, K. (2007) 'Breast cancer: Origins and evolution', *Journal of Clinical Investigation*, 117(11), pp. 3155–3163. doi: 10.1172/JCI33295.

Prihantono P. Cancer Incidence and Mortality in a Tertiary Hospital in Indonesia: An 18-Year Data Review. *Ethiop J. Health Science* doi: 10.4314/ejhs.v33i3.15. 33(3):515-522.. May, 2023.

Proteinatlas.org. (2014). Tissue expression of PTN - Summary. [online] Available at: <https://www.proteinatlas.org/ENSG00000105894-PTN/tissue> [Accessed 4 Aug. 2024].

Rakha, E. A. *et al.* (2010) 'Breast cancer prognostic classification in the molecular era: The role of histological grade', *Breast Cancer Research*, 12(4). doi: 10.1186/bcr2607.

Riggio, Alessandra I., *et al.* "The Lingering Mysteries of Metastatic Recurrence in Breast Cancer." *British Journal of Cancer*, vol. 124, no. 1, 1 Jan. 2021, pp. 13–26, www.nature.com/articles/s41416-020-01161-4, <https://doi.org/10.1038/s41416-020-01161-4>.

Rizzo, P. *et al.* (2008) 'Rational targeting of Notch signaling in cancer', *Oncogene*, 27(38), pp. 5124–5131. doi: 10.1038/onc.2008.226.

Schmandt, R. E. *et al.* (2006) 'The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary', *Cancer Biology and Therapy*, 5(9), pp. 1136–1141. doi: 10.4161/cbt.5.9.2953.

Sethi, G., Sung, B. and Aggarwal, B. B. (2008) 'Nuclear factor- κ B activation: From bench to bedside', *Experimental Biology and Medicine*, 233(1), pp. 21–31. doi: 10.3181/0707-MR-196.

Sorrelle, N. (2019). The impact of Pleiotrophin on breast cancer progression (dissertation). The impact of pleiotrophin on breast cancer progression. UT Southwestern Medical Center, Dallas, Tex.

Sung, H. *et al.* (2021) 'Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries', *CA: A Cancer Journal for Clinicians*, 71(3), pp. 209–249. doi: 10.3322/caac.21660.

Surakasula, A., Nagarjunapu, G., & Raghavaiah, K. (2014). A comparative study of pre- and post-menopausal breast cancer: Risk factors, presentation, characteristics and management. *Journal of Research in Pharmacy Practice*, 3(1), 12. <https://doi.org/10.4103/2279-042x.132704>

Tsuji, W. and Plock, J. A. (2017) 'Breast Cancer Metastasis', *Introduction to Cancer Metastasis*, pp. 13–31. doi: 10.1016/B978-0-12-804003-4.00002-5.

Wang, X. (2020a) 'Pleiotrophin: Activity and mechanism', *Advances in Clinical Chemistry*, 98, pp. 51–89. doi: 10.1016/bs.acc.2020.02.003.

Wang, X. (2020b) 'Pleiotrophin: Activity and mechanism', *Advances in Clinical Chemistry*. Elsevier Inc., 98, pp. 51–89. doi: 10.1016/bs.acc.2020.02.003.

World Health Organization: WHO. (2024, October 16). Menopause. <https://www.who.int/news-room/fact-sheets/detail/menopause>

Zarychta, Elżbieta, and Barbara Ruskowska-Ciastek. "Cooperation between Angiogenesis, Vasculogenesis, Chemotaxis, and Coagulation in Breast Cancer Metastases Development: Pathophysiological Point of View." *Biomedicines*, vol. 10, no. 2, 27 Jan. 2022, p. 300, <https://doi.org/10.3390/biomedicines10020300>.

Zhou, J. *et al.* (2018) 'A meta-Analysis on the role of pleiotrophin (PTN) as a prognostic factor in cancer', *PLoS ONE*, 13(11), pp. 1–14. doi: 10.1371/journal.pone.0207473.